Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III ...

R CHOP re treatment offers durable responses in patients with late relapse diffuse large b cell lymphoma, with a 2-year time ...

First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers The medians were not ...

Please provide your email address to receive an email when new articles are posted on . The regimen conferred a 71% complete response rate among older adults with newly diagnosed DLBCL. Median PFS and ...

Chemotherapy drugs can shrink tumors or kill stray cancer cells left behind after surgery or radiation. It’s also a systemic treatment, meaning its purpose is to kill cancer cells throughout your body ...

Please provide your email address to receive an email when new articles are posted on . The addition of lenalidomide to R-CHOP chemotherapy improved survival outcomes among patients with newly ...

To participate in this study, patients were required to have a diagnosis of de novo DLBCL; be treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone (R-CHOP) with or without ...

The replacement of vincristine with Velcade (bortezomib) in the R-CHOP regimen for the treatment of transplantation-ineligible patients with newly diagnosed mantle cell lymphoma improved overall ...

This trial was looking at a short course of chemotherapy with a new drug called Zevalin for people over 60 years of age with diffuse large B cell non Hodgkin lymphoma. Zevalin is a radio labelled ...